Search

everythinglearnresearchcommunity

for

Search:↓

Cyanidin 3-O-arabinoside may help treat a common form of hair loss by protecting cells against aging and improving cell function.

Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.

PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

A man developed skin issues from cancer medication, which improved with specific treatments.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Tofacitinib, a hair regrowth treatment, may worsen acne.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.